To help support our investigations, my colleagues and I have gathered the largest collection of pediatric neuroblastoma cases ever assembled. As a result, we moved some of these discoveries toward new therapies, a number of which are now in clinical trials. In the past few years, our team at Children's Hospital has been able to identify the main genes associated with this cancer. Our challenge is to impact clinical practice - an effort we approach with urgency and a large measure of recent success. We strive to be the worldвЂ™s leading neuroblastoma research and treatment center as we work to exponentially increase our understanding of this cancer and its underlying biology. To learn more and make a difference as quickly as possible, I developed a laboratory and translational research program at Children's Hospital to help us focus on the genetic abnormalities in hereditary and sporadic neuroblastoma.

I later became convinced that neuroblastoma is a genetic disease, and that we could make critical insights by discovering the genes that cause the cancer. I've been interested in this disease since before medical school, when I had the opportunity to work with noted scientists Drs. My own specialty is neuroblastoma, an often intractable cancer that starts in young nerve cells and can be extremely aggressive. As we make new discoveries, our goal is to bring them quickly to young patients. We design studies to help benefit children who have refractory or relapsed diseases for which treatment options may be limited. We are one of the nationвЂ™s leaders in early phase clinical research that intently focuses on improving pediatric cancer cure rates and minimizing long-term side effects. At Children's Hospital of Philadelphia, I work with a team of world-class clinicians and scientists dedicated to rapidly translating research about childhood cancers from the laboratory to the patient.

Proton jon mari 2